Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
What is the 2-year progression-free survival (PFS) for patients who, having achieved CR/VGPR following PAD therapy, do not receive any further treatment until clinical indication of relapse? This question is addressed separately for patients who are minimal residual disease positive (MRD+), and those who are MRD negative (MRD-), at end of induction chemotherapy.
Inclusion criteria
- Multiple myeloma